Study guide

6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

Key Takeaways Explain This Topic AI

Motivational Interviewing (MI) is a collaborative, person-centered counseling style grounded in the MI Spirit (Partnership, Acceptance, Compassion, Evocation); its primary goal is to resolve ambivalence and elicit the patient's own intrinsic motivation for change while actively suppressing the clinician's confrontational 'righting reflex.'

The core communication skills of MI encompass OARS (Open-ended questions, Affirmations, Reflective listening [differentiating simple vs complex/double-sided reflections], and Summaries) to strategically evoke and amplify Change Talk (DARN-CAT: Desire, Ability, Reasons, Need; Commitment, Activation, Taking steps) while rolling with sustain talk without argumentation.

The Transtheoretical Model (TTM / Stages of Change) delineates six stages: Precontemplation (validate autonomy, raise doubt), Contemplation (explore ambivalence, tip decisional balance), Preparation (co-create quit plan, set quit date), Action (coping skills, optimize pharmacotherapy), Maintenance (relapse prevention, lifestyle restructuring), and Recurrence (normalize, analyze lapse chain, rapidly re-engage).

Cognitive Behavioral Therapy (CBT) focuses on functional analysis of drug-taking behavior (Antecedents, Behaviors, Consequences; the 'ABC model'), cognitive restructuring of permission-giving beliefs, and coping skills training (refusal assertiveness, craving management via 'urge surfing,' delay, and distraction).

Contingency Management (CM) leverages operant conditioning through systematic, tangible positive reinforcement (escalating voucher schedules with reset contingencies or fishbowl prize draws) tied strictly to objective biological endpoints (negative urine toxicology), yielding the highest effect sizes (d = 0.6–0.8) among all psychosocial treatments for stimulant and cannabis use disorders; Dialectical Behavior Therapy (DBT) incorporates 'dialectical abstinence' and TIPP distress tolerance skills.

Last updated: September 2026

6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

Quick Answer: Behavioral therapies provide the psychotherapeutic scaffolding for addiction recovery. Motivational Interviewing (MI) (Miller & Rollnick) is a collaborative, person-centered method built on the MI Spirit (PACE: Partnership, Acceptance, Compassion, Evocation) ; it utilizes OARS skills (Open-ended questions, Affirmations, Reflective listening, Summaries) to draw out Change Talk (DARN-CAT) and resolve ambivalence while suppressing the clinician's righting reflex . The Transtheoretical Model (TTM) structures interventions across six discrete stages of change (Precontemplation → \to → Contemplation → \to → Preparation → \to → Action → \to → Maintenance → \to → Recurrence), requiring stage-matched clinical strategies. Cognitive Behavioral Therapy (CBT) utilizes functional analysis (Antecedents, Behaviors, Consequences) and craving management strategies such as "urge surfing" (riding out cravings like ocean waves without acting). Contingency Management (CM) applies operant conditioning, delivering escalating tangible rewards with reset contingencies for verified biological abstinence (negative urine drug screens), demonstrating the highest effect sizes (d = 0.6–0.8) for stimulant and cannabis disorders. Dialectical Behavior Therapy (DBT) incorporates dialectical abstinence and TIPP distress tolerance skills for co-occurring emotional dysregulation.

1. Motivational Interviewing (MI): Philosophy, The MI Spirit & The Righting Reflex

Developed by William R. Miller and Stephen Rollnick, Motivational Interviewing (MI) is an evidence-based, goal-oriented communication method designed to strengthen a person's intrinsic motivation for and commitment to change by eliciting and exploring their own reasons for change within an atmosphere of acceptance and compassion.

The Four Pillars of the MI Spirit (PACE)

MI is fundamentally a clinical way of being with patients, rather than a set of mechanical techniques. The "MI Spirit" is encapsulated by the acronym PACE :

Partnership: A collaborative, active alliance between two equal experts. The clinician is an expert in clinical science and pharmacotherapy; the patient is the absolute expert in their own lived experience, values, and motivations. The relationship is horizontal, eschewing top-down authoritarian confrontation.

Acceptance: Grounded in Carl Rogers’ humanistic psychology, acceptance comprises four core dimensions: (1) Absolute Worth (unconditional positive regard and human dignity); (2) Accurate Empathy (active understanding of the patient's internal frame of reference); (3) Autonomy Support (acknowledging and respecting the patient's irrevocable right and capacity for self-direction); and (4) Affirmation (recognizing the patient's inherent strengths, efforts, and intentions).

Compassion: A dedicated, benevolent commitment to actively pursue the welfare and best interests of the patient without secondary self-interest or institutional coercion.

Evocation: The fundamental premise that the internal motivation, wisdom, and capacity for change already reside within the patient. The clinician’s role is to evoke (draw out) the patient's own arguments and desires for change, rather than attempting to instill or install external logic, fear, or advice. ┌───────────────────────────────────┐

  • │ THE MI SPIRIT │
  • │ (PACE) │
  • └─────────────────┬─────────────────┘
  • ┌──────────────────┬─────────┴────────┬──────────────────┐
  • ▼ ▼ ▼ ▼
  • [Partnership] [Acceptance] [Compassion] [Evocation]
  • (Horizontal alliance, (Absolute worth, (Promoting patient (Drawing out
  • shared expertise) empathy, autonomy) welfare & dignity) internal wisdom)
  • The Righting Reflex: Definition & Clinical Dangers

The Righting Reflex is the clinician's automatic, well-intentioned impulse to fix what is broken, lecture the patient on health risks, provide unsolicited advice, or argue for the benefits of change when confronted with ambivalence or unhealthy behaviors.

The Paradoxical Effect: When a clinician succumbs to the righting reflex (e.g., saying, "If you don't quit smoking, your COPD will put you on oxygen!" ), an ambivalent patient is psychologically compelled to argue the opposing side ( "Well, smoking is the only thing that calms my nerves!" ). By voicing the counter-arguments, the patient literally talks themselves out of changing , entrenching their resistance and sustain talk.

APRN Rule: Suppress the righting reflex. Whenever you feel the urge to correct, argue, or persuade, pause and formulate an open-ended question or an empathetic reflection.

  • 2. Core Micro-Skills (OARS) & Deciphering Change Talk (DARN-CAT)
  • The OARS Micro-Skills Framework

The communicative engine of MI is built upon four fundamental verbal skills, denoted by the acronym OARS :

Open-Ended Questions: Questions that cannot be answered with a simple "yes," "no," or static fact. They invite the patient to reflect, elaborate, and explore their perspectives ( "What are some of the things you value about cannabis, and what are some things that concern you?" ).

Affirmations: Genuine, specific statements of appreciation that recognize patient strengths, resilience, positive traits, and past efforts ( "You showed remarkable determination by managing to attend today’s appointment despite experiencing severe withdrawal symptoms." ).

Reflective Listening (The Core Engine of MI): The clinician makes a declarative statement that reflects back the patient's underlying meaning, emotion, or ambivalence:

Simple Reflections: Paraphrasing or repeating the explicit content stated by the patient, conveying understanding without adding new meaning.

Complex Reflections: Going beneath the surface to identify unexpressed feelings, underlying values, metaphors, or implicit ambivalence ( "You feel torn—smoking provides your only break from caregiving duties, but you feel intense guilt when your children smell it on you." ).

Double-Sided Reflections: Joining both sides of the patient's ambivalence using the conjunction "and" rather than "but" ( "On one hand, cannabis relieves your severe evening anxiety, and on the other hand, you're exhausted from spending thousands of dollars each month and feeling groggy every morning." ).

Summaries: Periodically organizing and synthesizing what the patient has communicated, linking disparate themes together, and providing a launching pad to transition the dialogue forward.

Change Talk vs Sustain Talk: The DARN-CAT Taxonomy

Sustain Talk: Patient speech that favors maintaining the status quo, continuing substance use, or resisting change ( "I don't think I can ever sleep without smoking a joint." ).

Change Talk: Any patient speech that moves in the direction of change, reduced use, or recovery. Research demonstrates that the more a patient articulates Change Talk during a clinical session, the higher the probability of successful behavioral change . ┌─────────────────────────┐

  • │ CHANGE TALK │
  • └────────────┬────────────┘
  • ┌───────────────────────┴───────────────────────┐
  • ▼ ▼
  • [PREPARATORY CHANGE TALK] [MOBILIZING CHANGE TALK]
  • (DARN) (CAT)
  • ├── Desire ("I want to...") ├── Commitment ("I will...")
  • ├── Ability ("I can...") ├── Activation ("I am ready to...")
  • ├── Reasons ("It would help me...") └── Taking Steps ("I started by...")
  • └── Need ("I must...")

Category Component Definition Clinical Example

Preparatory D esire Statements of wanting, wishing, or hoping for change "I really want to get my lungs healthy again so I can run with my daughter."

Preparatory A bility Statements regarding personal capacity or self-efficacy "I know I managed to stay completely abstinent for 4 months two years ago."

Preparatory R easons Specific rationales, benefits, or arguments for change "If I stop spending money on vape cartridges, I could pay off my credit card debt."

Preparatory N eed Expressions of internal urgency or necessity (without specific reasons) "I just can't keep living like this; something has to change before I lose my job."

Mobilizing C ommitment Explicit promises, pledges, or contracts to act "I promise you that I will not buy any cigarettes when I leave the clinic today."

Mobilizing A ctivation Expressions of readiness or willingness to act (short of full commitment) "I am prepared to fill the varenicline prescription and throw out my lighters."

Mobilizing T aking Steps Concrete behavioral actions already taken toward the goal "Yesterday, I cleaned out my car and threw away all my rolling papers and ashtrays."

Strategic Evocation & Rolling with Discord

Importance and Confidence Rulers: Asking: "On a scale of 1 to 10, where 1 is not at all ready and 10 is completely ready, how ready are you to stop smoking?" When the patient answers (e.g., "A 5"), the follow-up question is critical: "Why did you choose a 5 and not a 2 or 3?" This forces the patient to articulate their own internal reasons for change (Change Talk).

Rolling with Discord (Sustain Talk): Never argue or confront resistance. Instead, roll with it through reflection, reframing, or siding with the negative ( "You feel like everyone is pressuring you, and right now you're not sure you're ready to give up something that feels so comforting." ).

3. Stages of Change: The Transtheoretical Model (TTM)

Developed by James Prochaska and Carlo DiClemente, the Transtheoretical Model (TTM) conceptualizes health behavior modification not as a single dichotomous event, but as an iterative, circular progression through six discrete stages of change . Matching the clinical intervention to the patient's specific stage is vital to prevent therapeutic rupture and disengagement. ┌────────────────────────┐

  • │ PRECONTEMPLATION │ ◀───┐
  • │ ("Not ready", >6 mos) │ │
  • └───────────┬────────────┘ │
  • ▼ │
  • ┌────────────────────────┐ │
  • │ CONTEMPLATION │ │
  • │ ("Getting ready", <6m) │ │
  • └───────────┬────────────┘ │
  • ▼ │
  • ┌────────────────────────┐ │
  • │ PREPARATION │ │
  • │ ("Ready", <30 days) │ │
  • └───────────┬────────────┘ │
  • ▼ │
  • ┌────────────────────────┐ │
  • │ ACTION │ │
  • │ ("Changing", 0–6 mos) │ │
  • └───────────┬────────────┘ │
  • ▼ │
  • ┌────────────────────────┐ │
  • │ MAINTENANCE │ │
  • │ ("Sustaining", >6 mos) │ │
  • └───────────┬────────────┘ │
  • │ │
  • ▼ │
  • ┌────────────────────────┐ │
  • │ RECURRENCE / RELAPSE │ ────┘
  • │ (Normalize, re-engage) │
  • └────────────────────────┘
  • Stage-Matched Clinical Interventions Matrix

Stage of Change Patient Mindset & Characteristics Primary Clinical Goal Evidence-Based APRN Interventions

1. Precontemplation Unaware of problem, in denial, or demoralized; no intention to change within the next 6 months . Raise awareness; evoke doubt; validate autonomy. Validate lack of readiness; avoid unsolicited advice; explore personal values; offer harm reduction and non-judgmental information.

2. Contemplation Aware a problem exists; actively ambivalent ("fence-sitting"); considering change within 6 months . Resolve ambivalence; tip the decisional balance toward change. Explore pros and cons of use vs quitting; elicit DARN change talk; use importance/confidence rulers; explore discrepancy between goals and behavior.

3. Preparation Intends to take action within the next 30 days ; may have made small behavioral steps. Formulate a clear, realistic action plan; bolster self-efficacy. Set a specific target quit date; select pharmacotherapies (Dual NRT, varenicline); identify high-risk triggers; enlist social support; remove paraphernalia.

4. Action Actively modified behavior within the past 0 to 6 months ; high vulnerability to relapse. Support behavioral execution; troubleshoot hurdles. Optimize pharmacotherapy dosing and side effect management; teach urge surfing; develop refusal assertiveness; reinforce self-efficacy.

5. Maintenance Sustained behavioral change for > 6 >6 > 6 months ; consolidating lifestyle integration. Prevent relapse; stabilize long-term recovery capital. Identify subtle relapse warning signs; develop coping strategies for unexpected stressors; celebrate milestones; transition pharmacotherapies when appropriate.

6. Recurrence (Relapse) Resumption of substance use following abstinence; feelings of guilt, shame, and failure. De-stigmatize; prevent demoralization; re-engage in care. Normalize relapse as part of a chronic disease; conduct functional analysis of the lapse chain; identify learned lessons; rapidly re-enter Preparation/Action.

4. Cognitive Behavioral Therapy (CBT) for Substance Use Disorders

Rooted in the principles of social learning theory and classical/operant conditioning, Cognitive Behavioral Therapy (CBT) views substance use as a learned, maladaptive coping behavior maintained by internal and external reinforcements.

Functional Analysis: The ABC Model

The cornerstone of CBT is the functional analysis (identifying the "5 W's": Who, What, When, Where, and Why ), examining the behavioral sequence through the ABC Model :

Antecedents (Triggers): The internal and external cues that precede and stimulate the urge to use substance:

External Triggers: Specific people (smoking buddies), places (bars, designated smoking areas), times of day (morning wake-up, driving), paydays, or physical items (lighters, rolling papers).

Internal Triggers: Negative affect (sadness, anger, anxiety), physical sensations (fatigue, nicotine withdrawal, visceral pain), or positive celebrations.

Behaviors: The drug-seeking and drug-consuming actions (e.g., purchasing, rolling, lighting, puffing), including cognitive self-talk ( "I’ve had a terrible day, I deserve this cigarette" ).

Consequences: The immediate and delayed outcomes:

Immediate Reinforcement: Rapid neurochemical dopamine release, relief of withdrawal, tension reduction (strongly reinforces behavior via operant conditioning).

Delayed Negative Consequences: Guilt, financial loss, respiratory coughing, interpersonal conflict, health deterioration.

Craving Management: "Urge Surfing"

Pioneered by G. Alan Marlatt, "Urge Surfing" is a mindfulness-based CBT intervention that reframes how patients respond to cravings:

The Ocean Wave Metaphor: Cravings are not permanent, inexorably rising mountains that inevitably lead to use unless acted upon. Instead, cravings are like ocean waves : they begin small, gather power, reach a crest (peak) within 10 to 20 minutes , and then naturally collapse and dissipate.

Clinical Technique: Instead of fighting, suppressing, or giving in to the craving, the patient practices "surfing" the urge. The patient mentally steps back and observes the craving with curious, non-judgmental detachment—tracking somatic sensations (chest tightness, dry mouth, racing pulse) and watching the wave crest and recede without taking a puff.

The 15-Minute Rule (Delaying): When hit with an intense craving, the patient agrees to wait 15 minutes before acting. During that window, the patient engages in an alternate competing behavior (e.g., drinking cold water, brisk walking, calling a support person); in > 90 % >90\% > 90% of instances, the crest has passed.

  • 5. Contingency Management (CM) & Dialectical Behavior Therapy (DBT)
  • Contingency Management (CM): Operant Conditioning in Addiction

Contingency Management (CM) is an evidence-based behavioral intervention grounded in B.F. Skinner's operant conditioning principles. CM systematically provides immediate, tangible, positive reinforcement (e.g., vouchers, retail gift cards, cash prizes) contingent upon objective, biochemically verified behavioral targets (most commonly point-of-care negative urine toxicology screens or attendance).

Unrivaled Effect Sizes: Meta-analyses consistently demonstrate that Contingency Management yields the largest effect sizes ( d = 0.60 to 0.80 d = 0.60\text{ to }0.80 d = 0.60 to 0.80 ) of any psychosocial treatment for substance use disorders, displaying unmatched efficacy in stimulant (cocaine, methamphetamine) and cannabis use disorders , where FDA-approved pharmacotherapies are lacking.

Escalating Voucher-Based Reinforcement: Patients receive vouchers exchangeable for goods/services. The monetary value of the voucher escalates consecutively for each consecutive negative drug screen submitted (e.g., Screen 1 = $10, Screen 2 = $15, Screen 3 = $20).

The Reset Contingency (Crucial Mechanism): If a patient misses a scheduled screening or submits a positive urine screen, the reinforcement schedule undergoes a reset : the voucher value immediately resets back to the initial baseline level ($10). However, to prevent demoralization, modern protocols incorporate a rapid return contingency where 2 to 3 consecutive negative screens restore the voucher value back to its highest previous tier.

Fishbowl (Prize-Based) Method (Nancy Petry): To reduce program costs while maintaining powerful behavioral reinforcement through a variable-ratio schedule , patients drawing slips from a "fishbowl" for submitting negative screens. A typical fishbowl of 100 slips contains:

  • 50% Praise Slips: "Good job! Keep it up!" (verbal affirmation, $0)
  • 40% Small Prizes: $1 to $5 vouchers for toiletries, snacks, bus passes
  • 9% Medium Prizes: $20 vouchers for groceries, electronics
  • 1% Jumbo Prize: $100 major prize [Biochemically Verified Negative Drug Screen]
  • │
  • ┌──────────────┴──────────────┐
  • ▼ ▼
  • [Negative Test Result] [Positive or Missed Screen]
  • │ │
  • ▼ ▼
  • [Tangible Immediate Reward] [Withhold Reinforcement]
  • │ │
  • ▼ ▼
  • [Escalate Reward Tier] [TRIGGER RESET CONTINGENCY]
  • (Consecutive negatives build (Voucher value drops back to baseline;
  • escalating voucher values) requires 2–3 consecutive negatives to restore)
  • Dialectical Behavior Therapy (DBT) Adaptations for SUD

Developed by Marsha Linehan, Dialectical Behavior Therapy (DBT) has been specifically adapted for patients with substance use disorders, particularly those with co-occurring Borderline Personality Disorder, severe emotional dysregulation, or chronic self-harm.

Dialectical Abstinence: A clinical synthesis between two seemingly irreconcilable polar opposites:

Thesis (100% Unrelenting Abstinence): The patient and clinician make an uncompromising, total commitment to absolute abstinence from substances today, planning exhaustively for high-risk situations.

Antithesis (Radical Acceptance of Lapses): If a lapse occurs, instead of catastrophic shaming or abandoning therapy (the "abstinence violation effect"), the clinician and patient practice radical acceptance without judgment, rapidly conducting a chain analysis to identify vulnerabilities, repairing relationships, and immediately returning to the pursuit of abstinence.

TIPP Distress Tolerance Crisis Skills: When acute emotional dysregulation or panic-driven drug cravings exceed cognitive capacity, the patient utilizes the somatic TIPP skills to rapidly alter neurobiology and downregulate sympathetic locus coeruleus hyperactivity:

Skill Physiological Mechanism Practical Application Protocol

T — Temperature Activates the parasympathetic mammalian dive reflex ; triggers rapid vagal bradycardia and dampens sympathetic surge. Submerge face in a bowl of cold/ice water (10–15°C / 50–59°F) while holding breath for 15 to 30 seconds .

I — Intense Exercise Metabolizes excessive circulating catecholamines (epinephrine/norepinephrine); discharges motor agitation. Perform 15 to 20 minutes of high-intensity aerobic activity (sprinting, jumping jacks, rapid stairs).

P — Paced Breathing Stimulates the vagus nerve and activates the parasympathetic nervous system via respiratory sinus arrhythmia. Slow breathing to 5–6 breaths per minute ; inhale deeply into belly for 4 seconds, exhale slowly for 7 seconds (exhale longer than inhale).

P — Paired Muscle Relaxation Promotes somatic neuromuscular release; breaks physical rigidity and tension loops. Inhale and deeply tense a specific muscle group for 5 seconds; exhale while completely releasing and mentally stating "Relax."